Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS228 in complicated urinary tract infection
2017-002292-26Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ancremonam in complicated urinary tract infection (cUTI) and urinary tract infection (UTI), sponsored by Novartis. Primary endpoints: Plasma pharmacokinetic parameters of LYS228 and Urine pharmacokinetic parameters of LYS228. Started Dec 2017; status: terminated.
02
Drugs
ancremonam
03
Conditions
complicated urinary tract infection (cUTI)urinary tract infection (UTI)
Beyond the preview
Go deeper on 2017-002292-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002292-26.